Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 838-841

  Lakey, David L ^a   Treanor, John J ^b   Betts, Robert F ^b   Smith, Gale E ^b   Thompson, Juliette ^b   Sannella, Edith ^b   Reed, George ^b   Wilkinson, Bethanie E ^b   Wright, Peter F ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; TRIPLE VACCINE;

ADULT; ANTIGEN PURIFICATION; ANTIGENICITY; ARTICLE; BACULOVIRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMBINANT DNA TECHNOLOGY; VACCINATION; VIRUS INACTIVATION;

EID: 0029837041     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.838     Document Type: Article

References (15)

1. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:24-44.
2. Perotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 1985;122:468-76.
3. Centers for Disease Control and Prevention. Update: influenza activity - United States and worldwide and composition of the 1992-1993 influenza vaccine. MMWR Morb Mortal Wkly Rep 1992;41:315-23.
4. Centers for Disease Control and Prevention. Prevention and Control of Influenza: Part I. Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Surveill Summ 1994;43(RR-9).
5. Centers for Disease Control and Prevention. Final results: Medicare influenza vaccine demonstration-selected states, 1988-1992. MMWR Morb Mortal Wkly Rep 1993;42:601-4.
6. Mullooly JP, Bennett MD, Hombrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-52.
7. Robertson JS, Bootman JS, Newman R, et al. Structural changes in the hemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 1987;160:31-7.
8. Katz J, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989;160:191-8.
9. Govaert TME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in the elderly people: randomized double blinded placebo controlled trial. BMJ 1993;307:988-90.
10. Fedson DS. Influenza prevention and control. Past practices and future prospects. Am J Med 1987;82(suppl 6A):42.
11. Harley VR, Mather KA, Power BE, McKimm-Breschkin JL, Hudson PJ. Characterization of an avian influenza virus nucleoprotein expressed in E. coli and in insect cells. Arch Virol 1990;113:267-77.
12. Nagy Z, Rajnavolgyi E, Hollosi M, et al. The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection. Scand J Immunology 1994;40:281-91.
13. Murphy BR, Phelan MA, Nelson DL, et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981;13:554-60.
14. Foster DA, Talsma A, Furumoto-Dawson A. Influenza vaccine effectiveness in preventing hospitalizations for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307.
15. Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995;171:1595-9.